# Capecitabine in Metastatic Breast and GI Cancers

> **NCT02595320** · PHASE2 · UNKNOWN · sponsor: **Qamar Khan** · enrollment: 200 (actual)

## Conditions studied

- Breast Cancer
- Gastrointestinal Cancer

## Interventions

- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02595320
- **Lead sponsor:** Qamar Khan
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-10-05
- **Primary completion:** 2022-12
- **Final completion:** 2023-12
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2021-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02595320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02595320, "Capecitabine in Metastatic Breast and GI Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02595320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*